<DOC>
	<DOCNO>NCT01614717</DOCNO>
	<brief_summary>This investigation prospective , randomize , single-blinded multicenter design . The purpose study evaluate benefit atrial-synchronous biventricular ( BiV ) pace severely symptomatic hypertrophic obstructive cardiomyopathy ( HOCM ) patient severe Left Ventricular Outflow Tract ( LVOT ) obstruction implant Cardiac Resynchronization Therapy - Pacing ( CRT-P ) device . Randomization - Implant perform ( CRT-P ) . - Patients randomize 1:1 either Treatment Group ( Optimized Biventricular ( DDD ) pace ) Control Group ( Back-up Atrial ( AAI ) pace ) first 12 month : - Treatment Group . The patient´s device program optimized DDD BiV pace - Control Group . The patient´s device program back-up pacing AAI . - After 12 month , patient initially randomize Treatment Group ( Optimized DDD Pacing ) continue group . The patient initially randomize Control Group ( AAI Back-up Pacing ) change Treatment Group ( Optimized DDD Pacing ) . And patient follow 12 month .</brief_summary>
	<brief_title>Triple Chamber Pacing Hypertrophic Obstructive Cardiomyopathy ( HOCM ) Patients - TRICHAMPION STUDY</brief_title>
	<detailed_description>Data collection - In clinic Follow ups ( FU ) : Enrollment , Baseline , Implant , Pre-discharge , 3 month ( M ) , 12 M , 15 M 24 M. - Phone call FU : 6 M , 9 M , 18 M 21 M .</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Cardiomyopathy , Hypertrophic</mesh_term>
	<criteria>1 . Unequivocal diagnosis hypertrophic cardiomyopathy ( HCM ) , basis 2dimensional echocardiographic demonstration hypertrophy ( wall thickness ≥15 mm ) nondilated Left Ventricle ( Left Ventricle End Diastolic Diameter ( LVEDD ) &lt; 55mm ) confirm Core Lab Echo ( Appendix I ) . 2 . Significant resting ( provoke ) LV outflow tract obstruction , basis peak LVOT gradient ≥50 mmHg , estimate continuous wave Doppler confirm Core Lab Echo ( Appendix I ) . 3 . Presence refractory symptom ( exertional dyspnea chest pain ) despite optimal treatment betablockers and/or verapamil least 3 month ( NYHA class &gt; II ) . 4 . Patients refuse contraindication septal myectomy septal ablation ( i.e. , comorbidity , inappropriate coronary anatomy septal ablation ) , prefer cardiac pacing , high risk develop heart block follow septal myectomy septal ablation . 6 . Patient 's age 18 year great . 7 . Patients must indicate understanding study willingness participate sign appropriate informed consent form . 8 . Patients must willing able comply study requirement . 1 . Known cause cardiac hypertrophy infiltrative cardiomyopathy , aortic stenosis severe uncontrolled hypertension . 2 . Permanent persistent atrial fibrillation . 3 . Previous septal myectomy septal ablation . 4 . Any indication permanent pacing , except HOCM . 5 . Any indication Implantable Cardioverter Defibrillator ( ICD ) . 6 . Systemic disease would preclude completion protocol . 7 . Any disability limitation correctly understand complete study ( physical , intellectual , logistical ) . 8 . Patients life expectancy &lt; 24 month ( base investigator assessment ) . 9 . Patients may potentially pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Hypertrophic Obstructive Cardiomyopathy</keyword>
	<keyword>Cardiac Resynchronization Therapy</keyword>
</DOC>